Staar Surgical shareholders reject merger, company stays independent

Staar Surgical ( (STAA) ) has shared an announcement.

On August 4, 2025, STAAR Surgical Company agreed to be acquired by Alcon Research, LLC through a merger with a subsidiary, but the companies terminated the merger agreement effective January 6, 2026, with no termination fees owed by any party and each side bearing its own transaction-related costs. At a special shareholders’ meeting held on January 6, 2026, STAAR investors, representing about 87.9% of the company’s voting power, rejected both the proposal to adopt the merger agreement and the related advisory executive compensation plan, leaving the company to continue independently rather than proceed with the previously announced transaction.

The most recent analyst rating on (STAA) stock is a Hold with a $30.75 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

Staar Surgical’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s financial challenges and bearish technical indicators weigh heavily on the score. The valuation is also weak due to negative earnings. However, the potential merger with Alcon offers a positive outlook, though it is not included in the weighted score due to the exclusion of corporate events.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical Company is a medical device maker focused on ophthalmic surgery, specializing in implantable lenses and other vision-correction technologies for the global eye-care market.

Average Trading Volume: 1,203,501

Technical Sentiment Signal: Sell

Current Market Cap: $1.19B

Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.